Condition

Stage IVC Verrucous Carcinoma of the Oral Cavity

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting0

Common interventions4

Lead sponsors shown3

Clinical trials

3 shown

Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung CancerNCT02245100 · 2014-07-22

COMPLETED

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck CancerNCT01528137 · 2012-05-01

TERMINATED

Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerNCT00068497 · 2003-08-01

COMPLETED

Common interventions

Laboratory biomarker analysisOTHER2 Cytology specimenOTHER1 gefitinibDRUG1 talactoferrinBIOLOGICAL1

Leading sponsors

National Cancer Institute (NCI)1 Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University1 Stanford University1

Trial status mix

COMPLETED2

TERMINATED1

Phase mix

NA1

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.